Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(8 sites)
Australia
Investigational Site Number : 001-203, Brisbane, Queensland Investigational Site Number : 001-201, Melbourne, Victoria Bosnia and Herzegovina
Investigational Site Number : 001-402, Mostar Investigational Site Number : 001-401, Sarajevo New Zealand
Investigational Site Number : 001-301, Auckland South Africa
Investigational Site Number : 001-801, Pretoria Investigational Site Number : 001-803, Pretoria Investigational Site Number : 001-804, Vereeniging